These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 28112819)

  • 1. Non-muscle-invasive bladder cancer: Intravesical treatments beyond Bacille Calmette-Guérin.
    Packiam VT; Johnson SC; Steinberg GD
    Cancer; 2017 Feb; 123(3):390-400. PubMed ID: 28112819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: A review.
    Saluja M; Gilling P
    Int J Urol; 2018 Jan; 25(1):18-24. PubMed ID: 28741703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer.
    Herr HW; Dalbagni G
    BJU Int; 2013 May; 111(6):984-7. PubMed ID: 23351086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin.
    Steinberg RL; Thomas LJ; Nepple KG
    Urol Oncol; 2016 Jun; 34(6):279-89. PubMed ID: 26777259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer.
    Steinberg RL; Nepple KG; Velaer KN; Thomas LJ; O'Donnell MA
    Urol Oncol; 2017 Dec; 35(12):670.e7-670.e14. PubMed ID: 28801026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage combination intravesical immunotherapy with Bacillus Calmette-Guérin and interferon-α2B: impact on recurrence, progression, and survival.
    Prasad SM; Eyre S; Loughlin KR
    Hosp Pract (1995); 2013; 41(4):31-9. PubMed ID: 24145587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage therapeutic strategies for bacillus Calmette-Guerin failure.
    Hassler MR; Shariat SF; Soria F
    Curr Opin Urol; 2019 May; 29(3):239-246. PubMed ID: 30762670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer.
    Crijnen J; De Reijke TM
    Expert Opin Emerg Drugs; 2018 Jun; 23(2):135-147. PubMed ID: 29730950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage Therapy for Non-muscle-invasive Bladder Cancer: Novel Intravesical Agents.
    Khaled D; Taylor J; Holzbeierlein J
    Urol Clin North Am; 2020 Feb; 47(1):119-128. PubMed ID: 31757295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy.
    Barlow L; McKiernan J; Sawczuk I; Benson M
    BJU Int; 2009 Oct; 104(8):1098-102. PubMed ID: 19389012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune therapies in non-muscle invasive bladder cancer.
    Ho PL; Williams SB; Kamat AM
    Curr Treat Options Oncol; 2015 Feb; 16(2):5. PubMed ID: 25757877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Intravesical Bacillus Calmette-Guérin Immunotherapy in Patients with Non-Muscle-Invasive Bladder Cancer Presenting with Asymptomatic Bacteriuria: A Systematic Review.
    Poletajew S; Zapała P; Radziszewski P
    Urol Int; 2017; 99(1):1-5. PubMed ID: 28601885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Candidates for Salvage Therapy: The Past, Present, and Future of Defining Bacillus Calmette-Guérin Failure.
    Becker REN; Kates MR; Bivalacqua TJ
    Urol Clin North Am; 2020 Feb; 47(1):15-21. PubMed ID: 31757296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
    Lamm D; Brausi M; O'Donnell MA; Witjes JA
    Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies.
    Kamat AM; Willis DL; Dickstein RJ; Anderson R; Nogueras-González G; Katz RL; Wu X; Barton Grossman H; Dinney CP
    BJU Int; 2016 May; 117(5):754-60. PubMed ID: 26032953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.
    Yates DR; Brausi MA; Catto JW; Dalbagni G; Rouprêt M; Shariat SF; Sylvester RJ; Witjes JA; Zlotta AR; Palou-Redorta J
    Eur Urol; 2012 Dec; 62(6):1088-96. PubMed ID: 22959049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy.
    Gallagher BL; Joudi FN; Maymí JL; O'Donnell MA
    Urology; 2008 Feb; 71(2):297-301. PubMed ID: 18308107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of Bacillus Calmette-Guérin therapy in non-muscle-invasive bladder cancer: Definition and treatment options.
    Gual Frau J; Palou J; Rodríguez O; Parada R; Breda A; Villavicencio H
    Arch Esp Urol; 2016 Sep; 69(7):423-33. PubMed ID: 27617552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer.
    Packiam VT; Richards J; Schmautz M; Heidenreich A; Boorjian SA
    Curr Opin Urol; 2021 May; 31(3):178-187. PubMed ID: 33742981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.